Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study.

Autor: Pencina KM; Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre-Royal Victoria Hospital, 1001 Boulevard Décarie, Montréal, Québec, H4A 3J1, Canada.; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Thanassoulis G; Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre-Royal Victoria Hospital, 1001 Boulevard Décarie, Montréal, Québec, H4A 3J1, Canada., Pencina MJ; Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre-Royal Victoria Hospital, 1001 Boulevard Décarie, Montréal, Québec, H4A 3J1, Canada.; Duke University School of Medicine, Biostatistics and Bioinformatics, DCRI, Durham, NC, USA., Toth PP; CGH Medical Center, Sterling, IL, USA.; Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sniderman AD; Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre-Royal Victoria Hospital, 1001 Boulevard Décarie, Montréal, Québec, H4A 3J1, Canada. allansniderman@hotmail.com.
Jazyk: angličtina
Zdroj: Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Dec 19; Vol. 23 (1), pp. 448. Date of Electronic Publication: 2024 Dec 19.
DOI: 10.1186/s12933-024-02525-3
Abstrakt: Objectives: Whether "prediabetes" merits particular clinical attention beyond the management of associated risk factors is controversial, particularly given the expansion of the definition of prediabetes from HbA1c 6.0-6.4% to 5.7-6.4%. Accordingly, we compared the risk of atherosclerotic cardiovascular disease (ASCVD) and type II diabetes mellitus (DM) risk in male and female participants with prediabetes and HbA1c 5.7-6.0% (low) versus 6.1-6.4% (high) to examine whether preventive recommendations should prioritize treating blood sugar or obesity, the major determinants of risk of DM versus other causes of ASCVD, such as lipids and blood pressure.
Research Design and Methods: 10-year risks of ASCVD and DM risk were determined separately in 296,470 women and men, age 40-73, from UK Biobank, free of ASCVD and DM at baseline. Cox proportional hazards regression with adjustment for conventional risk factors and Kaplan-Meier estimators were used with low (HbA1c 5.7-6.0%) and high prediabetes (HbA1c 6.1-6.4%) as primary exposuress with further stratification and adjustment for waist circumference.
Results: In multivariate-adjusted models, low and high prediabetes was associated with increased risk of ASCVD versus normal HbA1c in both women (HR = 1.08, 95% CI 1.01,1.15 in low prediabetes and 1.25, 95% CI 1.14,1.38 in high prediabetes) and men (HR = 1.18, 95%CI 1.11,1.24 in low prediabetes and 1.27, 95% CI 1.17,1.38 in high prediabetes). The associations with new onset DM were substantially more potent, achieving HR of 4.05, 95%CI 3.73,4.40 in low prediabetic women versus 14.22, 95% CI 13.06,15.49 in high pre-diabetic women and 4.45, 95% CI 4.12,4.80 in low prediabetic men versus 15.59, 95% CI 14.43,16.85 in high pre-diabetic men. Furthermore, increasing waist circumference in low prediabetic men and all prediabetic women was associated with meaningful increase in DM risk.
Conclusions: The risks of progression to both new onset DM and ASCVD are significantly greater in the prediabetic population. This underscores the importance of preventing the development of DM and efforts to reduce cardiometabolic risk through optimizing multiple risk factors in both categories of prediabetes. Risk modification by waist circumference suggests weight and glucose lowering therapies should be targeted at those with highest risks.
Competing Interests: Declarations. Competing interests: Dr. Karol Pencina reports funding from the non-profit Doggone Foundation. Dr. George Thanassoulis has participated in advisory boards or speaker bureaus for Amgen, Regeneron/Sanofi, HLS therapeutics, Ionis, Servier, Novartis, Silence and has received grant funding from Servier and Ionis. Dr. Michael Pencina reports funding from the non-profit Doggone Foundation, consulting fees from Cleerly Inc and advisory board fees from Eli Lilly and Janssen. Dr. Peter Toth is a member of the speaker’s bureau for Amgen, Lilly, and Novo-Nordisk; he is a consultant to Lilly, Merck, and Novartis. Dr. Allan Sniderman has no conflict of interest.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: